EnPlusOne Biosciences

About EnPlusOne Biosciences

EnPlusOne Biosciences is a cutting-edge startup operating in the biotechnology sector. The company specializes in the development and commercialization of advanced RNA synthesis technologies. Specifically, EnPlusOne Bio has secured a worldwide, exclusive licensing agreement to commercialize a novel, controlled enzymatic RNA oligonucleotide synthesis technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. This technology allows for more precise and efficient production of RNA molecules, which are crucial for various applications in research, diagnostics, and therapeutics.

The primary clients of EnPlusOne Bio include pharmaceutical companies, research institutions, and biotechnology firms. These clients utilize RNA molecules for drug development, genetic research, and diagnostic tests. By providing a more efficient and controlled method of RNA synthesis, EnPlusOne Bio aims to enhance the capabilities of these organizations, enabling them to achieve more accurate results and faster development times.

EnPlusOne Bio operates within the broader life sciences market, which encompasses sectors such as molecular diagnostics, synthetic biology, and environmental sciences. The company’s business model is based on licensing its proprietary RNA synthesis technology to other firms and institutions. Additionally, EnPlusOne Bio may offer custom RNA synthesis services, providing tailored solutions to meet the specific needs of its clients.

Revenue generation for EnPlusOne Bio primarily comes from licensing fees and service contracts. By offering a unique and highly specialized technology, the company positions itself as a valuable partner for organizations looking to advance their RNA-related research and development efforts.

In summary, EnPlusOne Biosciences is a biotech startup focused on revolutionizing RNA synthesis. It serves pharmaceutical companies, research institutions, and biotech firms, operating in the life sciences market. The company makes money through licensing its technology and offering custom synthesis services.